Blog
RSS FeedPosted by Michael Wonder on 13 Oct 2023
Outcomes of the September 2023 PBAC intracycle meeting
13 October 2023 - The outcomes from the September 2023 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 20 Jul 2023
Changes to CADTH’s rapid response service
20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
Posted by Michael Wonder on 21 Jun 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with lenvatinib ...
Posted by Michael Wonder on 21 Jun 2023
Dapagliflozin propanediol monohydrate for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
21 June 2023 - NICE has published final evidence-based recommendations on the use of dapagliflozin propanediol monohydrate for the treatment ...
Posted by Michael Wonder on 25 Oct 2022
Budget October 2022–23: strengthening Medicare
25 October 2022 - The Australian Government’s 2022-23 Budget begins the task of strengthening Medicare after a decade of cuts and ...
Posted by Michael Wonder on 07 Oct 2022
COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk
4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...
Posted by Michael Wonder on 16 Aug 2022
GPs demand action to fix ‘disintegrating’ Medicare
17 August 2022 - Doctors have issued the federal government with an urgent demand for more Medicare funding, warning general ...
Posted by Michael Wonder on 15 Aug 2022
One stop shop in Medicare shake-up
16 August 2022 - Doctors may be able to spend more time with patients, treat patients after-hours, and employ nurses, ...
Posted by Michael Wonder on 10 Aug 2022
The situation in New Zealand can only be described as dire
11 August 2022 - The available evidence for 2022 suggests the innovative pharmaceutical industry has very little interested in preparing/lodging ...
Posted by Michael Wonder on 17 Jun 2022
NICE recommends new targeted treatment for early breast cancer
16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...
Posted by Michael Wonder on 26 Oct 2021
Cystic fibrosis medicine added to PHARMAC's options for investment list
27 October 2021 - PHARMAC has announced that Vertex’s triple combination modulator therapy, known in some countries as Trikafta, has ...
Posted by Michael Wonder on 12 Oct 2021
NICE guidance on inclisiran should be reconsidered
12 October 2021 - Recommendation is premature without data on cardiovascular outcomes. ...
Posted by Michael Wonder on 27 Jun 2021
Overcharging doctors exposed under Medical Cost Finder revamp
28 June 2021 - A new government website will expose Australian doctors who are overcharging their patients and reveal the stingiest ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...
Posted by Michael Wonder on 07 May 2021
Avelumab not recommended as a maintenance treatment of urothelial cancer after platinum-based chemotherapy
7 May 2021 - NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of locally advanced or ...